Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)
Technology appraisal
Summary (source: NICE)
Reference: TA1089
Type: Technology appraisal
Published: 13 August 2025
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) is technology appraisal TA1089, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 13 August 2025. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.